KIMBERLY WYATT: Open Payments
NPI 1538490297 · LONGVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,424 in 85 payments from 17 companies in 2025. Trend: 2023 $401 · 2024 $1,027 · 2025 $1,424
Food & beverage: $1,424
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $367 |
| UCB, Inc. | 12 | $239 |
| Amgen Inc. | 16 | $219 |
| Novartis Pharmaceuticals Corporation | 6 | $141 |
| AstraZeneca Pharmaceuticals LP | 5 | $77 |
| Lilly USA, LLC | 4 | $67 |
| Aurinia Pharma U.S., Inc. | 3 | $59 |
| Radius Health, Inc. | 3 | $48 |
| PFIZER INC. | 2 | $36 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $35 |
Products named: Bimzelx, SKYRIZI, Otezla, COSENTYX, SAPHNELO, RINVOQ, TALTZ, ENBREL.
Industry payments across TX — which companies pay providers there.
